视神经脊髓炎谱系疾病生物靶向治疗研究进展  

Research progress on biological targeted therapy for neuromyelitis optica spectrum disorder

作　　者：张梦洁 秦新月[1] ZHANG Mengjie;QIN Xinyue(Department of Neurology,The First Affiliated Hospital of Chongqing Medical University,Chongqing 400010,China)

机构地区：[1]重庆医科大学附属第一医院神经内科,重庆400010

出　　处：《西南医科大学学报》2024年第4期289-294,共6页Journal of Southwest Medical University

摘　　要：视神经脊髓炎谱系疾病(neuromyelitis optica spectrum disorder,NMOSD)是一种自身免疫性中枢神经系统炎性脱髓鞘疾病,主要侵犯视神经和脊髓,具有高复发、高致残的特点,严重影响了患者的生活质量。在NMOSD的病程管理中,序贯治疗尤为重要。近年来,生物靶向制剂治疗NMOSD较传统免疫抑制剂显示出更好的疗效。本文就目前全球已获批用于治疗NMOSD的3类生物靶向制剂做一评述,包括补体抑制剂、IL-6受体阻断剂和B淋巴细胞耗竭剂,以期为NMOSD的生物靶向制剂治疗提供借鉴与参考。Neuromyelitis optica spectrum disorder(NMOSD)is an autoimmune,inflammatory demyelinating disease of the cen-tral nervous system,primarily affecting the optic nerves and spinal cord.It is characterized by high relapse rates and significant disabil-ity,severely impacting patients'quality of life.Sequential therapy plays a crucial role in the management of NMOSD.In recent years,biological therapies have demonstrated superior efficacy compared to traditional immunosuppressants in treating NMOSD.Aiming to provide reference and guidance for the biotargeted treatment of NMOSD,this article reviewed three types of biological agents which have been approved globally for the treatment of NMOSD,including complement inhibitors,IL-6 receptor blockers,and B lymphocyte depleting agents.

关 键 词：视神经脊髓炎谱系疾病 生物靶向治疗 免疫治疗 自身免疫性脱髓鞘疾病 

分 类 号：R744.52[医药卫生—神经病学与精神病学]